VASH2 Antibody

1. VASH2 may promote drug resistance of breast cancer cells through regulating ABCG2 via the AKT signaling pathway. PMID: 29039601
2. These results suggest that VASH-2 could play an important role in the pathogenesis of renal diseases, and that VASH-2 is closely associated with hypertension and impaired glucose tolerance. PMID: 29042694
3. VASH1 and VASH2 but not SVBP alone, increased detyrosination of -tubulin, and purified vasohibins removed the C-terminal tyrosine of -tubulin. PMID: 29146869
4. These results suggest that VASH2 plays an important role in gastric tumor progression via the accumulation of cancer-associated fibroblasts PMID: 28960674
5. The present study suggests a protective effect of miR-200b/c on high glucose induced human retinal microvascular endothelial cell line dysfunction by inhibiting VASH2. PMID: 28882646
6. VASH2 expression is positively correlated with FGF2 expression and promotes angiogenesis in human luminal breast cancer by transcriptional activation of fibroblast growth factor 2 through non-paracrine mechanisms. PMID: 27702660
7. These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer cells via JUN-dependent transactivation of RRM2. PMID: 28327155
8. identified a novel UPS regulatory system in which essential domain architecture (VASH-PS) of VASHs, comprising regions VASH191-180 and VASH280-169 , regulate the cytosolic punctate structure formation in the absence of SVBP. PMID: 27879017
9. The results indicate that VASH2 played a significant role in the epithelial-mesenchymal transition by modulating the TGF-beta signaling. PMID: 28064471
10. to the best of our knowledge, these results are the first clinical data indicating that nuclear VASH2, but not cytoplasmic VASH2, promotes cell proliferation by driving the cell cycle from the G0/G1 to S phase. PMID: 26177649
11. MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma PMID: 25269476
12. Suggest that overexpression of VASH2 in pancreatic ductal adenocarcinoma accelerated the pace of tumor development toward a more serious malignant phenotype and was associated with a poor clinical outcome. PMID: 25916042
13. VASH1 and VASH2 showed distinctive localization and opposing function on the fetoplacental vascularization. PMID: 25184477
14. VASH2 overexpression downregulated wild-type p53. PMID: 24595063
15. VASH2 expressed in serous ovarian carcinoma cells promoted tumor growth and peritoneal dissemination by promoting angiogenesis. PMID: 22826464
16. This is the first study to report differences in the intracellular localization of the VASH2 protein and, hence, a new research direction on the study of VASH2 PMID: 23615928
17. vasohibin-1 and vasohibin-2 mRNA are expressed in gastric cancer cells and in tumor-associated macrophages (TAMs), and their expressions are altered by hypoxia. PMID: 22438034
18. VASH2 contributes to the angiogenesis in hepatocellular carcinoma via an Small vasohibin binding protein-mediated paracrine mechanism. PMID: 22614011
19. Data suggest that VASH1 is expressed in vascular endothelium to terminate angiogenesis; VASH2 appears to be expressed in other cells (primarily mononuclear leukocytes) to promote angiogenesis. [REVIEW] PMID: 23100270

Show More

Hide All

HGNC: 25723

OMIM: 610471

KEGG: hsa:79805

UniGene: Hs.96885